Table 1 Effect of TKIs approved for the treatment of cancer on glucose homeostasis

From: Cancer, obesity, and diabetes: TKIs exert multiple effects on glucose homeostasis

TKI

Approved indications

Effect on glucose levels

Imatinib

CML, CEL, ALL, and GIST

• Hyperglycaemic effect7

• Hypoglycaemic effect10

Nilotinib

CML

Hyperglycaemic effect4

Dasatinib

CML and ALL

Hypoglycaemic effect11

Gefitinib

NSCLC

Hyperglycaemic effect12

Erlotinib

NSCLC, gastic cancer, and PDAC

Hypoglycaemic effect13

Sorafenib

RCC and HCC

Hypoglycaemic effect5

Sunitinib

RCC, GIST, and PNET

• Hyperglycaemic effect14

• Hypoglycaemic effect15

  1. ALL, acute lymphoblastic leukaemia; CEL, chronic eosinophilic leukaemia; CML, chronic myeloid leukaemia; GIST, gastrointestinal stromal tumour; HCC, hepatocellular carcinoma; NSCLC, non-small-cell lung carcinoma; PDAC, pancreatic ductal adenocarcinoma; PNET, pancreatic neuroendocrine tumour; RCC, renal-cell carcinoma.
PowerPoint slide
Back to article page